pyridoxamine has been researched along with Complications of Diabetes Mellitus in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "It appears that pyridoxamine ameliorated lipid peroxidation and insulin resistance in KK-A(y)/Ta mice." | 3.75 | Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice. ( Gohda, T; Hagiwara, S; Horikoshi, S; Ishikawa, Y; Murakoshi, M; Ohara, I; Tanimoto, M; Tomino, Y; Toyoda, H, 2009) |
| "Pyridoxamine is a post-Amadori AGE inhibitor-that is, an "Amadorin"-whereas aminoguanidine primarily scavenges reactive dicarbonyl precursors to AGEs." | 2.43 | Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. ( Chen, Y; Khalifah, RG; Wassenberg, JJ, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 10 (90.91) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Murakoshi, M | 1 |
| Tanimoto, M | 1 |
| Gohda, T | 1 |
| Hagiwara, S | 1 |
| Ohara, I | 1 |
| Toyoda, H | 1 |
| Ishikawa, Y | 1 |
| Horikoshi, S | 1 |
| Tomino, Y | 1 |
| Metz, TO | 1 |
| Alderson, NL | 1 |
| Chachich, ME | 1 |
| Thorpe, SR | 2 |
| Baynes, JW | 2 |
| Jakus, V | 1 |
| Rietbrock, N | 1 |
| Voziyan, PA | 1 |
| Hudson, BG | 2 |
| Khalifah, RG | 2 |
| Chen, Y | 1 |
| Wassenberg, JJ | 1 |
| Padival, S | 1 |
| Nagaraj, RH | 1 |
| Jain, SK | 1 |
| Ahmad, MS | 1 |
| Pischetsrieder, M | 1 |
| Ahmed, N | 2 |
| Thornalley, PJ | 1 |
| Booth, AA | 1 |
| Price, DL | 1 |
| Rhett, PM | 1 |
4 reviews available for pyridoxamine and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Advanced glycation end-products and the progress of diabetic vascular complications.
Topics: Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Glycation End Products, Advanced; Glyco | 2004 |
Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage.
Topics: Animals; Diabetes Complications; Glycation End Products, Advanced; Humans; Maillard Reaction; Oxidat | 2005 |
Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Drug Design; Glycation End Product | 2005 |
Advanced glycation endproducts: what is their relevance to diabetic complications?
Topics: Blood Glucose; Diabetes Complications; Glycation End Products, Advanced; Glycosylation; Humans; Hype | 2007 |
7 other studies available for pyridoxamine and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice.
Topics: Adipose Tissue; Animals; CD36 Antigens; Diabetes Complications; Diabetes Mellitus, Experimental; Dia | 2009 |
Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications.
Topics: Animals; Arachidonic Acid; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Fatty Acids, Un | 2003 |
Pyridoxamine inhibits maillard reactions in diabetic rat lenses.
Topics: Aldehyde Reductase; Animals; Arginine; Chromatography, High Pressure Liquid; Diabetes Complications; | 2006 |
Vitamin B6 (pyridoxamine) supplementation and complications of diabetes.
Topics: Animals; Diabetes Complications; Dietary Supplements; Glycation End Products, Advanced; Haplorhini; | 2007 |
Aged garlic extract and S-allyl cysteine prevent formation of advanced glycation endproducts.
Topics: Aging; Antioxidants; Cysteine; Diabetes Complications; Electrophoresis, Polyacrylamide Gel; Free Rad | 2007 |
Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine.
Topics: Animals; Antigens; Cattle; Diabetes Complications; Diabetes Mellitus; Enzyme Inhibitors; Glycation E | 1996 |
Chelating activity of advanced glycation end-product inhibitors.
Topics: Amines; Antioxidants; Ascorbic Acid; Bromides; Chelating Agents; Copper; Diabetes Complications; Dia | 2001 |